Indian kids on growth hormone drug to be watched for side effects in new safety study

NCT ID NCT06587035

Recruiting now Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 35 times

Summary

This study tracks the safety of Somatrogon, a growth hormone medicine, in 50 children aged 3 and older with pediatric growth hormone deficiency (short stature). Participants are already prescribed the drug by their doctor and will be followed for up to 3 years for side effects. No new treatment is given—this is an observation-only study to see how safe the medicine is in routine care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DWARFISM, PITUITARY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Apollo Children's Hospital
RECRUITING

Chennai, Tamil Nadu, 600006, India
Apollo Speciality Hospital
RECRUITING

Madurai, Tamil Nadu, 625020, India
G Kuppuswamy Naidu Memorial Hospital
RECRUITING

Coimbatore, Tamil Nadu, 641037, India
Shivajoyti Clinic
RECRUITING

Bengaluru, Karnataka, 560008, India

Conditions

Explore the condition pages connected to this study.

DWARFISM, PITUITARY